Evidence map›Paper›PMID 28939108›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Differential response to doxorubicin in breast cancer subtypes simulated by a microfluidic tumor model.

Altug Ozcelikkale, Kyeonggon Shin, Victoria Noe-Kim, Bennett D Elzey, Zizheng Dong, Jian-Ting Zhang, Kwangmeyung Kim, Ick Chan Kwon, Kinam Park, Bumsoo Han

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues.Annual review of biomedical engineering · 2021
    Pooled it
  3. Article
  4. Review
  5. DNA Origami-Cyanine Nanocomplex for Precision Imaging of KRAS-Mutant Pancreatic Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. A timescale-guided microfluidic synthesis of tannic acid-FeJournal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  18. The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Altug OzcelikkaleSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Kyeonggon ShinSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Victoria Noe-KimSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, USA.
Bennett D ElzeyDepartment of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA; Purdue Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Zizheng DongDepartment of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, USA.
Jian-Ting ZhangDepartment of Pharmacology and Toxicology, Indiana University, Indianapolis, IN, USA.
Kwangmeyung KimBiomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea.
Ick Chan KwonBiomedical Research Institute, Korea Institute of Science and Technology, Seoul, South Korea.
Kinam ParkWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA.
Bumsoo HanSchool of Mechanical Engineering, Purdue University, West Lafayette, IN, USA; Purdue Center for Cancer Research, Purdue University, West Lafayette, IN, USA; Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA; Birck Nanotechnology Center, Purdue University, West Lafayette, IN, USA. Electronic address: bumsoo@purdue.edu.
Purdue University West Lafayette · USIndiana University – Purdue University Indianapolis · USKorea Institute of Science and Technology · KRCenter for Cancer Research · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Indiana Clinical and Translational Science Institute (UL1)UL1TR000006 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2012 to 2013
$5.6M
NCATS NIH HHS UL1 TR000006NCATS NIH HHS UL1 TR001108NCI NIH HHS HHSN261201400021CNCI NIH HHS P30 CA023168
6 · The paper itself

Abstract

Successful drug delivery and overcoming drug resistance are the primary clinical challenges for management and treatment of cancer. The ability to rapidly screen drugs and delivery systems within physiologically relevant environments is critically important; yet is currently limited due to lack of appropriate tumor models. To address this problem, we developed the Tumor-microenvironment-on-chip (T-MOC), a new microfluidic tumor model simulating the interstitial flow, plasma clearance, and transport of the drug within the tumor. We demonstrated T-MOC's capabilities by assessing the delivery and efficacy of doxorubicin in small molecular form versus hyaluronic acid nanoparticle (NP) formulation in MCF-7 and MDA-MB-231, two cell lines representative of different molecular subtypes of breast cancer. Doxorubicin accumulated and penetrated similarly in both cell lines while the NP accumulated more in MDA-MB-231 than MCF-7 potentially due to binding of hyaluronic acid to CD44 expressed by MDA-MB-231. However, the penetration of the NP was less than the molecular drug due to its larger size. In addition, both cell lines cultured on the T-MOC showed increased resistance to the drug compared to 2D culture where MDA-MB-231 attained a drug-resistant tumor-initiating phenotype indicated by increased CD44 expression. When grown in immunocompromised mice, both cell lines exhibited cell-type-dependent resistance and phenotypic changes similar to T-MOC, confirming its predictive ability for in vivo drug response. This initial characterization of T-MOC indicates its transformative potential for in vitro testing of drug efficacy towards prediction of in vivo outcomes and investigation of drug resistance mechanisms for advancement of personalized medicine.

Indexed as

AnimalsAntibiotics, AntineoplasticBreast NeoplasmsCell Line, TumorCell SurvivalDoxorubicinFemaleHumansHyaluronan ReceptorsHyaluronic AcidMiceMicrofluidicsNanoparticlesTumor MicroenvironmentAntibiotics, AntineoplasticDoxorubicinHyaluronan ReceptorsHyaluronic AcidBreast cancerCancer stem cellChemoresistanceDoxorubicinDrug transportTumor-microenvironment-on-chip

Identifiers

PMID28939108
PMCPMC5723544
OpenAlexW2754940015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.